Medexus Pharmaceuticals (MEDX.F) Stock Overview
Operates as a pharmaceutical company in Canada and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
MEDX.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Medexus Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.96 |
| 52 Week High | CA$3.88 |
| 52 Week Low | CA$1.27 |
| Beta | 1.91 |
| 1 Month Change | -4.95% |
| 3 Month Change | -5.41% |
| 1 Year Change | 11.89% |
| 3 Year Change | 36.93% |
| 5 Year Change | -45.76% |
| Change since IPO | -47.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| MEDX.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.9% | 1.7% | -0.2% |
| 1Y | 11.9% | 3.2% | 20.3% |
Return vs Industry: MEDX.F exceeded the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: MEDX.F underperformed the US Market which returned 20.3% over the past year.
Price Volatility
| MEDX.F volatility | |
|---|---|
| MEDX.F Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MEDX.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MEDX.F's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 91 | Ken d'Entremont | www.medexus.com |
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Medexus Pharmaceuticals Inc. Fundamentals Summary
| MEDX.F fundamental statistics | |
|---|---|
| Market cap | US$64.79m |
| Earnings (TTM) | US$806.00k |
| Revenue (TTM) | US$105.66m |
Is MEDX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDX.F income statement (TTM) | |
|---|---|
| Revenue | US$105.66m |
| Cost of Revenue | US$42.21m |
| Gross Profit | US$63.45m |
| Other Expenses | US$62.65m |
| Earnings | US$806.00k |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.025 |
| Gross Margin | 60.05% |
| Net Profit Margin | 0.76% |
| Debt/Equity Ratio | 40.6% |
How did MEDX.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 11:02 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medexus Pharmaceuticals Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |